key: cord-1031865-ymfttol8 authors: Grodecki, Kajetan; Lin, Andrew; Razipour, Aryabod; Cadet, Sebastien; McElhinney, Priscilla A.; Chan, Cato; Pressman, Barry D.; Julien, Peter; Maurovich-Horvat, Pal; Gaibazzi, Nicola; Thakur, Udit; Mancini, Elisabetta; Agalbato, Cecilia; Menè, Robert; Parati, Gianfranco; Cernigliaro, Franco; Nerlekar, Nitesh; Torlasco, Camilla; Pontone, Gianluca; Slomka, Piotr J.; Dey, Damini title: Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19() date: 2020-11-19 journal: Metabolism DOI: 10.1016/j.metabol.2020.154436 sha: 3e48a419e2aba11a8e712cbe77fc69b1cad94441 doc_id: 1031865 cord_uid: ymfttol8 Aim We sought to examine the association of epicardial adipose tissue (EAT) quantified on chest computed tomography (CT) with the extent of pneumonia and adverse outcomes in patients with coronavirus disease 2019 (COVID-19). METHODS: We performed a post-hoc analysis of a prospective international registry comprising 109 consecutive patients (age 64 ± 16 years; 62% male) with laboratory-confirmed COVID-19 and noncontrast chest CT imaging. Using semi-automated software, we quantified the burden (%) of lung abnormalities associated with COVID-19 pneumonia. EAT volume (mL) and attenuation (Hounsfield units) were measured using deep learning software. The primary outcome was clinical deterioration (intensive care unit admission, invasive mechanical ventilation, or vasopressor therapy) or in-hospital death. RESULTS: In multivariable linear regression analysis adjusted for patient comorbidities, the total burden of COVID-19 pneumonia was associated with EAT volume (β = 10.6, p = 0.005) and EAT attenuation (β = 5.2, p = 0.004). EAT volume correlated with serum levels of lactate dehydrogenase (r = 0.361, p = 0.001) and C-reactive protein (r = 0.450, p < 0.001). Clinical deterioration or death occurred in 23 (21.1%) patients at a median of 3 days (IQR 1–13 days) following the chest CT. In multivariable logistic regression analysis, EAT volume (OR 5.1 [95% CI 1.8–14.1] per doubling p = 0.011) and EAT attenuation (OR 3.4 [95% CI 1.5–7.5] per 5 Hounsfield unit increase, p = 0.003) were independent predictors of clinical deterioration or death, as was total pneumonia burden (OR 2.5, 95% CI 1.4–4.6, p = 0.002), chronic lung disease (OR 1.3 [95% CI 1.1–1.7], p = 0.011), and history of heart failure (OR 3.5 [95% 1.1–8.2], p = 0.037). CONCLUSIONS: EAT measures quantified from chest CT are independently associated with extent of pneumonia and adverse outcomes in patients with COVID-19, lending support to their use in clinical risk stratification. Coronavirus disease 2019 (COVID-19) is a global pandemic and public health crisis of catastrophic proportions, with over 40 million confirmed cases worldwide as of October 20 th 2020 1 . Although the majority of patients present with no or mild symptoms, up to 20% develop severe disease requiring hospitalization, with 5-8% subsequently being admitted to the intensive care unit (ICU) 2 . Chest computed tomography (CT) is highly sensitive for the diagnosis of COVID-19 pneumonia 3 , and the extent of lung abnormalities reflects the disease stage [4] [5] [6] . Obesity has been shown to associate with critical illness, need for ICU admission, and prolonged hospitalization in patients with COVID-19 pneumonia 2, 7-12 , however the underlying pathophysiologic mechanisms remain unclear 13 . Epicardial adipose tissue (EAT) is an active endocrine organ which modulates the metabolic environment of both the coronary arteries and myocardium 14 . EAT volume measured on CT has been shown to associate with lung function in both healthy individuals and those with chronic lung disease [15] [16] [17] [18] . Further, CT-derived EAT attenuation (Hounsfield Units [HU] ) has an established association with cardiometabolic risk factors and circulating inflammatory markers 19, 20 . COVID-19 induces an immune-mediated systemic inflammatory response 21 and it has been postulated that EAT may transduce this inflammation to the heart 22, 23 . Moreover, ectopic intrapulmonary fat reservoirs could potentially facilitate viral infiltration and promote local lung inflammation 24, 25 . Few studies have evaluated the relationship of EAT measures with radiological and clinical severity of COVID-19 pneumonia 26, 27 . In this post-hoc analysis of a prospective, international, multicenter registry, we sought to examine the association of CT-derived quantitative EAT volume and J o u r n a l P r e -p r o o f Journal Pre-proof attenuation with pneumonia burden and adverse outcomes in hospitalized patients with COVID-19. This prospective, international, multicenter registry included centers from North America Chest CT was performed to aid in the triage of patients with a high clinical suspicion for COVID-19, in the setting of a pending or negative RT-PCR or comorbidities associated with severe illness from COVID-19. The CT images from each patient and the clinical database were fully anonymized and transferred to one coordinating center for core lab analysis. The study was conducted with the approval of local institutional review boards (Cedars-Sinai Medical Center IRB# study 617) and written informed consent was waived for fully anonymized data analysis. automatic tube current modulation (300-500 mAs), and slice thickness of 0.625 to 1.25 mm. Images were reconstructed using lung kernels specific for respective scanner vendors. All scans were obtained in the supine position during inspiratory breath-hold. Images were analyzed by two physicians (K.G. and A.L.) with 3 and 8 years of experience in chest CT, respectively, and who were blinded to clinical data. A standard lung window (width: Angeles, CA, USA). First, both lungs were segmented by a deep learning model based on U-Net architecture 28 . The acquired pulmonary mask and a second deep learning model trained with the Lung Tissue Research Consortium dataset were then used to compute lobe segmentations, with manual adjustments made by the reader as required 29 . The right lung was divided into upper, middle, and lower lobes with respect to the horizontal and oblique fissures; while the left lung was separated into upper and lower lobes by the oblique fissure. Lung lesions associated with COVID-19 pneumonia were then segmented using a semiautomated brush-like tool; the boundaries of which were delimited by a region-growing algorithm. These included ground glass opacities (GGO), consolidation, or pleural effusion according to the Fleischner Society lexicon (Figure 2A-B) 30 31 31 30 31 . Adaptive thresholds were used, defined by a fixed window around the HU of the selected voxel. Chronic lung abnormalities such as emphysema or fibrosis were excluded from segmentation, based on correlation with previous imaging and/or a consensus reading. GGO was defined as hazy opacities that did not obscure the underlying bronchial structures or pulmonary vessels; J o u r n a l P r e -p r o o f Journal Pre-proof consolidation as opacification obscuring the underlying bronchial structures or pulmonary vessels; and pleural effusion as a fluid collection in the pleural cavity. Total pneumonia volume was calculated by summing the volumes of the GGO and consolidation components. Total pneumonia burden was calculated as: total pneumonia volume / total lung volume x 100% 31 . The average time taken for full lung and lesion segmentation ranged from 10-20 minutes depending on patient anatomy and the extent of pneumonia. The axial distribution of lung abnormalities was visually classified as peripheral (predominantly outer one-third of the lung), central (predominantly inner two-thirds of the lung), or diffuse (no clear distribution pattern 6 . Difficult cases of visual or quantitative analysis were resolved by consensus. The presence of any breathing artifact was also noted. EAT was defined as all adipose tissue enclosed by the visceral pericardium 32, 33 . EAT volume and attenuation were quantified using a deep learning algorithm incorporated into research software (QFAT version 2.0; Cedars-Sinai Medical Center). The development and validation of this automated method have been described previously 32, 33 . Briefly, the limits of the heart were automatically defined as the pulmonary artery bifurcation (superior limit) to the posterior descending artery (inferior limit) and pericardial contours traced by the algorithm. For ungated CT data in our cohort, the pericardial contours were adjusted if needed. EAT volume (reported in mL) and mean attenuation (reported in HU) were automatically calculated from 3- The primary outcome was a composite of clinical deterioration (intensive care unit [ICU] admission, invasive mechanical ventilation, or vasopressor therapy) or death. The time to the first occurrence of any one of the components was documented. Chronic lung disease included asthma, chronic obstructive pulmonary disease, and/or obstructive sleep apnea. Chronic kidney disease was defined as eGFR <60 ml/min/1.73m 2 . Immunodeficiency was defined as active cancer treated with chemotherapy or human immunodeficiency virus infection. Patient symptoms were self-reported upon hospital admission. Serum levels of biomarkers were obtained at hospital admission. Data were tested for normality using the Shapiro-Wilk test. Continuous variables are expressed as mean ± standard deviation or median (interquartile range [IQR]), as appropriate. Categorical variables are presented as absolute numbers (percentage). Continuous variables were compared using the Student's t-test or nonparametric Mann-Whitney U-test, as appropriate. Categorical variables were compared using a Chi-square test. Correlations between continuous variables were assessed using the Spearman's rank correlation coefficient. We performed multivariate linear regression to examine the association of EAT measures with total pneumonia burden, adjusted for age, sex, and comorbidities previously shown to associate with severe illness from COVID-19 (diabetes mellitus, hypertension, smoking, chronic lung disease, history of coronary artery disease, and history of heart failure) 34, 35 . To evaluate the predictive value of EAT measures for the primary outcome, we performed multivariable logistic regression analysis, adjusted for total pneumonia burden and the above clinical parameters. Quantitative pneumonia burden and EAT volume were not normally distributed and hence normalized with logarithmic adjustment; base-2 log transformation was used as this represented doubling of the variable. We selected the optimum cutoffs for EAT volume by identifying the ROC values that maximized Youden's J statistic (sensitivity + specificity -1). A 2sided p-value <0.05 was considered statistically significant. All analyses were performed using Stata 14.0 (StataCorp, College Station, TX, USA). A total of 109 patients (age 64±16 years; 62% male) with laboratory-confirmed COVID-19 who underwent chest CT during their admission were included. The primary outcome occurred in 23 (21.1%) patients: 15 (65.2%) were admitted to ICU, 10 (43.5%) required mechanical ventilation, 10 (43.5%) required vasopressors, and 13 (56.5%) had in-hospital death. The median time from self-reported onset of symptoms to chest CT was 7 days (IQR 5-9 days), and the median time from chest CT to the occurrence of the primary outcome was 3 days (IQR 1-13 days). The remaining patients (n=86; 78.9%) did not require critical care or had been discharged alive at the time of data collection. Patients who experienced deterioration or died were older and had a greater number of comorbidities (Table 1) . No significant differences in body mass index (BMI) were observed between the two groups (p=0.526). Serum inflammatory markers were increased in patients with versus without the primary outcome (Table 1) . The median time from chest CT to positive RT-PCR testing was 0 (IQR 0-3) days. Breathing artifacts were observed in 18 (16.5%) cases. The prevalence and distribution of lung abnormalities were comparable between patients with and without the primary outcome, apart from pleural effusions (30.4% vs 9.3%, p=0.009) being more common in patients with clinical deterioration/death ( Figure 3A ). Median EAT attenuation in patients with versus without the primary outcome was -68.4 HU (IQR -76.4 --65.8) vs -73.0 HU (IQR -76.8 --68.6), with a trend toward statistical significance (p=0.077; Figure 3B ). In bivariate analysis, EAT volume was positively correlated with total pneumonia burden (r=0.29, p=0.006). In multivariable linear regression adjusted for clinical parameters, the total pneumonia burden was independently associated with EAT volume (β = 10.6, 95% CI 3.4 -17.8, p=0.005) and attenuation (β = 5.2, 95% CI 1.5 -8.9, p=0.004; Table 3 ) In multivariable logistic regression analysis, EAT volume (OR 5. Bivariate correlations between CT parameters, serum biomarkers, and clinical variables are presented in Table 5 . EAT volume had a moderate correlation with BMI and serum levels of lactate dehydrogenase and CRP; and a weak correlation with creatine kinase-MB levels and J o u r n a l P r e -p r o o f total pneumonia volume and burden. EAT attenuation was inversely correlated with lactate dehydrogenase levels. In this international multicenter study of patients with COVID-19, we examine the relationship between EAT quantified from chest CT with the extent of pneumonia and adverse outcomes in patients with COVID-19. We demonstrate that: (1) EAT volume and attenuation associate with the quantitative burden of COVID-19 pneumonia; and (2) an increasing EAT volume or attenuation independently predict clinical deterioration or death. Obesity has been identified as a risk factor for hospitalization and mechanical ventilation in acute respiratory illnesses such as H1N1 influenza 36 , and a similar trend is emerging in patients with COVID-19. Evidence shows that any degree of obesity (BMI ≥30 kg/m 2 ) associates with more advanced disease including respiratory and multiorgan failure in COVID-19, and morbid obesity (BMI ≥40 kg/m 2 ) confers a significantly worse prognosis compared to normal weight [7] [8] [9] [10] [11] . Although traditionally used to define obesity, BMI ≥30 kg/m 2 remains an indirect marker of excess body fat and does not account for the substantial regional and phenotypic variation in fat depots 14 EAT inflammation may be reflected by a higher CT attenuation of this fat depot 48 . Furthermore, J o u r n a l P r e -p r o o f angiotensin-converting enzyme 2 (ACE-2), used by SARS-CoV-2 to enter host cells, is expressed in several different cell-lines including adipocytes 49 . Given that ACE-2 upregulation is seen in adipocytes of patients with obesity and diabetes, EAT may serve as an important viral reservoir 50 . Finally, visceral fat accumulation, associated with reduced testosterone levels especially in older males, may influence the pathophysiology of COVID-19 through dysregulation of the growth hormone (GH)-insulin-like growth factor 1 (IGF1) axis 51 . It has been recently hypothesized that GH insufficiency may contribute to gender-related differences in COVID-19 52 . Indeed, our study showed an association of EAT, age, and male gender with the extent of pneumonia, underscoring the complex interplay between the endocrine and immune systems. The integration of EAT volume measurements into clinical risk scores for patients with COVID-19 has the potential to enhance in-hospital outcome prediction. Our deep learning-based method of EAT quantification from routine chest CT is rapid (<3 minutes per case); however more studies are required to determine whether this approach is applicable to different COVID- and thus we were unable to adjust for the potentially confounding effect of this obesity measure in our multivariable models. Finally, levels of serum biomarkers such as CRP, lactate dehydrogenase, and troponin were not uniformly available and thus not included in our risk prediction models to assess the independent effects of systemic inflammation or myocardial injury on outcomes; further studies are needed to assess these relationships. EAT parameters quantified from chest CT are independently associated with extent of pneumonia and adverse outcomes in patients with COVID-19, lending support to its use in clinical risk stratification. Male sex 16 J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f  An increasing EAT volume or attenuation independently predicts clinical deterioration or death.  EAT may contribute to the augmented systemic inflammatory response to COVID-19.  The integration of EAT measurements into clinical risk scores for patients with COVID-19 has the potential to enhance in-hospital outcome prediction. World Health Organization COVID-19 Situation Report -139 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection Well-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia Body mass index and the risk of COVID-19 across ethnic groups: Analysis of UK Biobank Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission Clinical Characteristics of Covid-19 in Letter to the Editor: Importance of metabolic health in the era of COVID-19 Obesity and impaired metabolic health in patients with COVID-19 Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations Association between thoracic fat measured using computed tomography and lung function in a population without respiratory diseases Pericardial fat is associated with impaired lung function and a restrictive lung pattern in adults: the Jackson Heart Study Epicardial adipose tissue in patients with chronic obstructive pulmonary disease Increased Epicardial Fat Volume Is Independently Associated with the Presence and Severity of Systemic Sclerosis Relation between cardiovascular disease risk factors and epicardial adipose tissue density on cardiac computed tomography in patients at high risk of cardiovascular events Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Does epicardial fat contribute to COVID-19 myocardial inflammation? Epicardial adipose tissue: fuel for COVID-19-induced cardiac injury? Obesity and SARS-CoV-2: A population to safeguard Targeting the Adipose Tissue in COVID-19 Visceral fat shows the strongest association with the need of intensive Care in Patients with COVID-19 Epicardial Fat Inflammation in severe COVID-19 Automatic lung segmentation in routine imaging is primarily a data diversity problem, not a methodology problem Lung tissue characterization for emphysema differential diagnosis using deep convolutional neural networks: SPIE Fleischner Society: glossary of terms for thoracic imaging Quantitative Burden of COVID-19 Pneumonia on Chest CT Predicts Adverse Outcomes: A Post-Hoc Analysis of a Prospective International Registry Fully Automated CT Quantification of Epicardial Adipose Tissue by Deep Learning: A Multicenter Study Deep Learning-Based Quantification of Epicardial Adipose Tissue Volume and Attenuation Predicts Major Adverse Cardiovascular Events in Asymptomatic Subjects Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study Obesity and its Implications for COVID-19 Mortality The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and J o u r n a l P r e -p r o o f vascular calcification in a community-based sample: the Framingham Heart Study Perivascular Adipose Tissue and Coronary Atherosclerosis: from Biology to Imaging Phenotyping Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease Cytokine release syndrome in severe COVID-19 Epicardial fat thickness is associated with severity of disease in patients with chronic obstructive pulmonary disease Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies Epicardial fat tissue in patients with psoriasis:a systematic review and meta-analysis Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters Is epicardial fat attenuation a novel marker of coronary inflammation? ACE2: from vasopeptidase to SARS virus receptor Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease Epicardial fat thickness significantly decreases after short-term growth hormone (GH) replacement therapy in adults with GH deficiency Is Growth Hormone Insufficiency the Missing Link Between Obesity, Male Gender, Age, and COVID-19 Severity? Obesity (Silver Spring). 2020. 53. Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report